Quit Like Sweden Urges Progressive Tobacco Control to Save Millions of Lives on World No Tobacco Day
29.5.2024 15:21:00 EEST | Business Wire | Press release
Millions of lives could be saved with a more progressive approach to tobacco control measures, says a new platform committed to encouraging countries to follow the Swedish Experience and become ‘smoke-free’. As the world gears up to observe World No Tobacco Day (WNTD) on May 31, Quit Like Sweden, launched earlier this year in Brazil, is calling for proven strategies to enhance the global fight against smoking.
Traditionally, WNTD has been marked exclusively by calls for the complete abandonment of smoking. However, Quit Like Sweden argues that it's time for policymakers, regulators, governments, the media, and the general public to engage in a meaningful discussion about the strategies that do reduce the devastating impacts of smoking and smoking-related illnesses.
Suely Castro, Founder of Quit Like Sweden, emphasized the need for a new approach, citing the Swedish Experience and remarkable progress in tobacco control.
"Each World No Tobacco Day, the international community argues that a world without cigarettes is the ultimate aim. But this World No Tobacco Day, instead of discussing what could be possible, it’s time to look at what is already being done by the only country that is close to quitting smoking: Sweden," said Suely Castro.
While Sweden has rigorously adopted smoking cessation and prevention measures, it has also enabled smokers to choose safer alternatives. This approach, based on what Ms Castro calls the three A's – which stand for the Accessibility, Acceptability, and Affordability of safer alternatives – has resulted in millions of Swedes choosing to leave cigarettes behind and switch to safer alternatives.
"In Sweden, one in four adults uses nicotine every day. While this is the same level as the rest of Europe, Sweden’s incidence of cancer is 41% lower, and smoking-related deaths in Sweden are less than half of smoking-related deaths in 24 of the other 26 EU countries”, Castro said.
“This is the case within European countries, which have similar regulations to those of Sweden, although not its comprehensive approach to eradicating smoking. Just imagine what the global impact of the full Swedish Experience could be.”
“We have the ability to save millions of lives just by replicating a model that has already worked so well for Sweden,” she said. "And there’s no better time to start that conversation than now.”
Background
Quit Like Sweden is a not-for-profit platform with the aim to encourage countries to take action to replicate the Swedish Experience in a comprehensive strategy that also includes measures and programmes focused on smoking cessation and prevention, and enabling people who smoke to choose alternatives instead.
We don’t advocate for the removal of measures and programmes that contribute to smoking cessation or prevention, and instead appeal to all policymakers in all countries, intergovernmental and non-governmental organizations to complement those measures and programmes.
Sweden Statistics
As a result of Sweden’s progressive tobacco control measures:
- Sweden is the only country in the world to officially be ‘smoke-free’, when its smoking prevalence falls below 5% later this year.
- Across Europe, the smoking rate is 5 times higher than Sweden’s.
- 24 of the 27 EU countries have a tobacco-related mortality rate at least twice as high as Sweden’s.
- Sweden’s incidence of cancer is 41% lower than the rest of Europe’s, which means 38% lower levels of total cancer deaths.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529797728/en/
Contact information
Media Inquiries & Interviews:
Suely Castro, Founder, Quit Like Sweden
suelycastro@quitlikesweden.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
